Paul G. Richardson, MD, on Isatuximab Plus Pomalidomide and Low-Dose Dexamethasone in Multiple Myeloma

Posted: Wednesday, July 14, 2021

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III results from the ICARIA-MM study, which showed that isatuximab plus pomalidomide improved the time to next treatment as well as disease progression on first subsequent therapy or death compared with pomalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. There was also a strong trend in overall survival benefit reported with the addition of isatuximab.